Federal Official Gazette
ANS NORMATIVE RESOLUTION No. 663, OF FEBRUARY 11, 2026
Amends Normative Resolution (RN) No. 465, of February 24, 2021, which provides for the List of Health Procedures and Events (Rol) within the scope of Supplementary Health, in order to regulate the mandatory coverage of the immunobiological drug risankizumab, for the treatment of moderate to severe active ulcerative colitis or ulcerative proctocolitis in adult patients, after failure, refractoriness, relapse or intolerance to anti-TNF therapy, in compliance with paragraphs 4, 7 and 8 of Article 10 of Law No. 9,656/1998.
ANS news
No updates.
Open public consultations
- CP 167. Subject: CP opened to collect criticism and suggestions regarding the preliminary recommendations contained in UAT No. 186 – Encorafenib, UAT No. 189 – Osimertinib and UAT No. 190 – Talazoparib. Deadline: Feb 10 to Mar 1.
Scheduled public hearings
There are no scheduled public hearings.
Open public calls for input
- A Public Call for Input (TPS) is hereby opened to receive suggestions on the priority Supplementary Health topics that will inform the composition of the 2026-2028 Regulatory Agenda of the National Supplementary Health Agency (ANS). Extension: February 27, 2026.
Open public calls
No updates.
Other news
Health Plans: Price adjustment may determine vote on Bill (PL)
Source: bsbaltafrequencia.com.br · read the full article
Sources: Federal Official Gazette (DOU) and the ANS website. Press items link to the original article. This brief is for information only and does not constitute legal advice.